Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Integrin alpha-3 (ITGA3), also known as CD49c, is a cell surface adhesion receptor that exclusively pairs with the integrin beta-1 (ITGB1) subunit to form the functional alpha-3/beta-1 heterodimer. This integrin complex acts as a primary receptor for extracellular matrix (ECM) proteins, particularly laminins (such as laminin-332), fibronectin, and collagen. It plays a critical role in cell-matrix adhesion, cell migration, tissue organization, and signal transduction. In oncology, ITGA3 is highly overexpressed in various solid tumors, including bladder, breast, pancreatic, ovarian, and head and neck cancers, where it promotes tumor progression, invasion, metastasis, and resistance to chemotherapy and immunotherapy. Consequently, ITGA3 has emerged as an attractive therapeutic target and prognostic biomarker. Therapeutic strategies under development include antibody-drug conjugates (ADCs) like 2E7-MMAE, which exploit the rapid internalization of ITGA3 to deliver cytotoxic payloads, and targeted oncolytic platforms like VAX-014, which utilize engineered bacterial minicells to selectively lyse ITGA3-expressing tumor cells. However, drug development targeting ITGA3 faces significant safety challenges; homozygous loss-of-function mutations in ITGA3 cause ILNEB syndrome, a severe multi-organ disorder characterized by interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, highlighting the potential for severe on-target toxicities in the lungs, kidneys, and skin.
Targeted cell lysis via pore-forming protein delivery, antibody-drug conjugation for intracellular payload delivery, and inhibition of cell adhesion and migration
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Integrin alpha-3 (ITGA3).